Smoking cessation: an economic analysis and review of varenicline
Open Access
- 1 June 2009
- journal article
- review article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 1, 25-34
- https://doi.org/10.2147/ceor.s4223
Abstract
Peer reviewed article authored by (Michele A Faulkner). Read article or submit your manuscript for publishing.Keywords
This publication has 33 references indexed in Scilit:
- Mood, Side-effects and Smoking Outcomes Among Persons With and Without Probable Lifetime Depression Taking VareniclineJournal of General Internal Medicine, 2009
- Suicidal ideation and varenicline: a possible case of mistaken adverse drug reaction?2008
- Varenicline as compared to bupropion in smoking-cessation therapy—Cost–utility results for Sweden 2003Respiratory Medicine, 2008
- Cost effectiveness analysis of smoking cessation interventionsAustralian and New Zealand Journal of Public Health, 2006
- Employer-sponsored insurance coverage of smoking cessation treatments.2006
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- VareniclineNature Reviews Drug Discovery, 2006
- Curbing the epidemic: governments and the economics of tobacco controlTobacco Control, 1999
- The Health Care Costs of SmokingNew England Journal of Medicine, 1997
- The Surgeon General's 1989 Report on Reducing the Health Consequences of Smoking: 25 Years of Progress.1989